The growing prevalence of autoimmune and blood disorders has put a spotlight on the science of hemostasis, the process of stopping bleeding and keeping blood within the damaged blood vessel. The coagulation/hemostasis analyzer market is expected to reach $4.84 billion by 2021, according to a report from MarketsandMarkets. Among the products, clinical laboratory analyzers are expected to account for the largest share of the market.
Some big name players are already strengthening their hemostasis portfolios. In December 2015, Mallinckrodt plc (NYSE: MNK) purchased a global portfolio of three hemostasis products from The Medicines Company (NASDAQ: MDCO) for an upfront payment of $175 million, and royalties of up to $235 million.
Some lesser known names have been shedding non-core assets to bolster its leadership position in hemostasis diagnostics. Barcelona-based Werfen Life Group S.A., through its in-vitro business, is a worldwide leader in hemostasis, critical care and autoimmunity in vitro diagnostic (IVD) solutions. Its hemostasis and critical care product lines, in 2015, had a global market share of 28 and 19%, ranking 1st and 2nd worldwide, respectively.
On January 19, Werfen announced it had divested one of its medical device subsidiaries, Bolton Medical Inc., to Terumo Corporation (OTC: TRUMF) for an undisclosed amount. Bolton Medical provides thoracic and abdominal stent graft systems for the treatment of aortic disease. Bolton Medical was one of two portfolio companies in Werfen’s medical devices unit.
A day later, the company announced its acquisition of Accriva Diagnostics Inc. from private equity giant Warburg Pincus for an undisclosed price. Accriva develops products in the areas of hemostasis management and point-of-care testing. Werfen plans to combine Accriva with one of its subsidiaries, Instrumentation Laboratory (IL).
The Accriva portfolio, including point-of-care (POC) diagnostic products for coagulation and anti-platelet therapy response, will allow IL to establish a market-leading position in hospital-based POC hemostasis testing, expand its position in POC critical care testing and complement its position in the hemostasis laboratory segment. Accriva is the fifth portfolio company in Werfen Life Group’s diagnostics unit.
In 2014, Accriva sold off its IRMA TruPoint product line, which includes a laboratory grade blood gas analyses device, to LifeHealth LLC. Following that transaction, Accriva began directing all of its development resources to its core hemostasis management diagnostic products.
